Breaking Finance News

A statement released earlier today by Needham about Cytokinetics (NASDAQ:CYTK) drops the target price to $12.00

Cytokinetics (NASDAQ:CYTK) had its target price lowered to $12.00 by Needham in a report released 11/23/2017. The new target price indicates a possible downside of -0.12% from the company's most recent stock price close.

On 11/22/2017, Morgan Stanley released a statement for Cytokinetics (NASDAQ:CYTK) bumped down the target price from $25.00 to $17.00 that suggested an upside of 0.25%.

Boasting a price of $13.65, Cytokinetics (NASDAQ:CYTK) traded -1.01% lower on the day. With the last stock price close down 4.99% from the two hundred day average, compared with the S&P 500 Index which has increased 0.01% over the date range. Cytokinetics has recorded a 50-day average of $14.77 and a two hundred day average of $13.95. Volume of trade was down over the average, with 402,408 shares of CYTK changing hands under the typical 450,903

Performance Chart

Cytokinetics (NASDAQ:CYTK)

With a total market value of $0, Cytokinetics has with a one year low of $8.77 and a one year high of $17.20 .

A total of 6 equity analysts have released a ratings update on CYTK. 1 brokerage rating the stock a strong buy, 5 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $19.17.

Brief Synopsis On Cytokinetics (NASDAQ:CYTK)

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.